Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Finding the right dose

Mark J Ratain1

  • 1Clinical Pharmacology and Pharmacogenics, The University of Chicago, IL, USA.

Clinical Advances in Hematology & Oncology : H&O
|November 1, 2005
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ivonescimab: The Next United States Food and Drug Administration Project Optimus Flashpoint?

JTO clinical and research reports·2026
Same author

Evaluating Perceived Value of Pharmacogenomic Testing After a Personalized Therapeutics Clinic Consultation.

Clinical and translational science·2026
Same author

<i>TPMT</i>-Cisplatin: Lessons in Citation Integrity and Scientific Oversight.

JCO oncology practice·2026
Same author

Dear Doctor: We Still Have No Idea of What Dose of Capecitabine You Should Prescribe.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Opportunities for Harmonization of US Food and Drug Administration Regulatory Decisions Exemplified by the Traditional Approval of Sotorasib and Panitumumab for Colorectal Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Potential alternative dosage strategies for patent-protected oral cancer drugs.

European journal of cancer (Oxford, England : 1990)·2025
Same journal

Clinical response with cabozantinib plus nivolumab, a first-line therapy in advanced renal cell carcinoma: a clinical case report.

Clinical advances in hematology & oncology : H&O·2026
Same journal

Active treatment in high-risk, early-stage CLL or SLL.

Clinical advances in hematology & oncology : H&O·2026
Same journal

Targeting human kallikrein 2 in prostate cancer.

Clinical advances in hematology & oncology : H&O·2026
Same journal

Targeting BRAF V600E mutations in metastatic colorectal cancer.

Clinical advances in hematology & oncology : H&O·2026
Same journal

The development of second-generation KRAS inhibitors.

Clinical advances in hematology & oncology : H&O·2026
Same journal

Clinical applications of PARP inhibitors in breast, ovarian, and prostate cancer: current insights and future directions.

Clinical advances in hematology & oncology : H&O·2026
See all related articles